Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Public ClinicalTrials.gov record NCT00326885. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-Arm, Open-Label, Phase II Study to Assess the Safety and Efficacy of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intraperitoneally in Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
Study identification
- NCT ID
- NCT00326885
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Neovii Biotech
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Interventions
- catumaxomab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2006
- Primary completion
- Nov 30, 2009
- Completion
- Jul 31, 2010
- Last update posted
- Oct 16, 2018
2006 – 2010
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center | Tucson | Arizona | — | — |
| University of San Diego | La Jolla | California | — | — |
| Stanford University Hospital and Clinics | Stanford | California | — | — |
| University of Miami | Miami | Florida | — | — |
| Florida Hospital Cancer Center | Orlando | Florida | — | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | — | — |
| University of Louisville Cancer Center | Louisville | Kentucky | — | — |
| Johns Hopkins Medical Institute | Baltimore | Maryland | — | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | — | — |
| Massachusetts General Hospital | Boston | Massachusetts | — | — |
| Wayne State University | Detroit | Michigan | — | — |
| Dartmouth-Hitchock Medical Center | Lebanon | New Hampshire | — | — |
| Columbia University Cancer center | New York | New York | — | — |
| Wake-Forest University | Winston-Salem | North Carolina | — | — |
| University of Oklahoma Health Science Center | Oklahoma City | Oklahoma | — | — |
| Magee Women's Hospital, University of Pittsburgh | Pittsburgh | Pennsylvania | — | — |
| The Methodist Hospital | Houston | Texas | — | — |
| Huntsman Cancer Institute | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00326885, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 16, 2018 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00326885 live on ClinicalTrials.gov.